MRK · DHC 10-KFeb 25 '25
“Merck & Co. Inc. (2) 55,102 0.8% 5,335 2.6% 2033”
ABBV · DHC 10-KFeb 25 '25
“Abbvie Inc. 197,976 3.0% 3,955 1.9% 2027”
MRK · CTMX 10-KMar 16 '26
“In the second quarter of 2024, CytomX announced a clinical collaboration with Merck to supply KEYTRUDA for evaluation of its combination with CX-801 in the Phase 1 study.”
ABBV · CTMX 10-KMar 16 '26
“The Varseta-M payload is a topoisomerase-1 inhibitor licensed from AbbVie (formerly ImmunoGen), tailored to have anti-tumor activity against EpCAM-expressing cancer types.”